• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于单样本基因集富集分析算法的低级别胶质瘤免疫特征及免疫亚型鉴定

Identification of Immunological Characteristics and Immune Subtypes Based on Single-Sample Gene Set Enrichment Analysis Algorithm in Lower-Grade Glioma.

作者信息

Zhu Yunyang, Feng Songwei, Song Zhaoming, Wang Zhong, Chen Gang

机构信息

Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, China.

Department of Obstetrics and Gynaecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.

出版信息

Front Genet. 2022 May 13;13:894865. doi: 10.3389/fgene.2022.894865. eCollection 2022.

DOI:10.3389/fgene.2022.894865
PMID:35646050
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9136245/
Abstract

Few breakthroughs have been achieved in the treatment of lower-grade glioma (LGG) in recent decades. Apart from the conventional pathological and histological classifications, subtypes based on immunogenomics would provide reference for individualized treatment and prognosis prediction. Our study identified four immunotypes of lower-grade glioma (clusters A, B, C, and D) by bioinformatics methods in TCGA-LGG and two CGGA datasets. Cluster A was an "immune-cold" phenotype with the lowest immune infiltration and longest survival expectation, whereas cluster D was an "immune-rich" subtype with the highest immune infiltration and poor survival expectation. The expression of immune checkpoints increased along with immune infiltration degrees among the clusters. It was notable that immune clusters correlated with a variety of clinical and immunogenomic factors such as age, WHO grades, IDH1/2 mutation, PTEN, EGFR, ATRX, and TP53 status. In addition, LGGs in cluster D were sensitive to cisplatin, gemcitabine, and immune checkpoint PD-1 inhibitors. RTK-RAS and TP53 pathways were affected in cluster D. Functional pathways such as cytokine-cytokine receptor interaction, antigen processing and presentation, cell adhesion molecules (CAMs), and ECM-receptor interaction were also enriched in cluster D. Hub genes were selected by the Matthews correlation coefficient (MCC) algorithm in the blue module of a gene co-expression network. Our studies might provide an immunogenomics subtyping reference for immunotherapy in LGG.

摘要

近几十年来,低级别胶质瘤(LGG)的治疗几乎没有取得突破性进展。除了传统的病理和组织学分类外,基于免疫基因组学的亚型可为个体化治疗和预后预测提供参考。我们的研究通过生物信息学方法在TCGA-LGG和两个CGGA数据集中确定了低级别胶质瘤的四种免疫类型(A、B、C和D簇)。A簇是一种“免疫冷”表型,免疫浸润最低,生存预期最长,而D簇是一种“免疫丰富”亚型,免疫浸润最高,生存预期较差。各簇中免疫检查点的表达随着免疫浸润程度的增加而升高。值得注意的是,免疫簇与多种临床和免疫基因组因素相关,如年龄、世界卫生组织分级、IDH1/2突变、PTEN、EGFR、ATRX和TP53状态。此外,D簇中的LGG对顺铂、吉西他滨和免疫检查点PD-1抑制剂敏感。RTK-RAS和TP53通路在D簇中受到影响。细胞因子-细胞因子受体相互作用、抗原加工和呈递、细胞黏附分子(CAMs)和ECM-受体相互作用等功能通路在D簇中也得到富集。通过基因共表达网络蓝色模块中的马修斯相关系数(MCC)算法选择了枢纽基因。我们的研究可能为LGG免疫治疗提供免疫基因组学亚型参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/9b3f2e576c40/fgene-13-894865-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/5c34be271a06/fgene-13-894865-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/535eac152c3d/fgene-13-894865-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/61b83d7015d2/fgene-13-894865-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/6c5aceaa37ee/fgene-13-894865-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/0387d239b2bb/fgene-13-894865-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/c36c3049422d/fgene-13-894865-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/8e386bd4177b/fgene-13-894865-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/5168cdefef17/fgene-13-894865-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/00c816ebcea0/fgene-13-894865-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/8c59cdc2bf92/fgene-13-894865-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/9ddb04a5e657/fgene-13-894865-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/9b3f2e576c40/fgene-13-894865-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/5c34be271a06/fgene-13-894865-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/535eac152c3d/fgene-13-894865-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/61b83d7015d2/fgene-13-894865-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/6c5aceaa37ee/fgene-13-894865-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/0387d239b2bb/fgene-13-894865-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/c36c3049422d/fgene-13-894865-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/8e386bd4177b/fgene-13-894865-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/5168cdefef17/fgene-13-894865-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/00c816ebcea0/fgene-13-894865-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/8c59cdc2bf92/fgene-13-894865-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/9ddb04a5e657/fgene-13-894865-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/efb2/9136245/9b3f2e576c40/fgene-13-894865-g012.jpg

相似文献

1
Identification of Immunological Characteristics and Immune Subtypes Based on Single-Sample Gene Set Enrichment Analysis Algorithm in Lower-Grade Glioma.基于单样本基因集富集分析算法的低级别胶质瘤免疫特征及免疫亚型鉴定
Front Genet. 2022 May 13;13:894865. doi: 10.3389/fgene.2022.894865. eCollection 2022.
2
Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.TYROBP 表达升高预示低级别胶质瘤患者预后不良和肿瘤免疫浸润程度高。
BMC Cancer. 2021 Jun 23;21(1):723. doi: 10.1186/s12885-021-08456-6.
3
Construction of a novel molecular typing and scoring system for anoikis distinguishes between different prognostic risks and treatment responsiveness in low-grade glioma.构建一种新型的无附著力细胞凋亡分子分型和评分系统,可区分低级别胶质瘤的不同预后风险和治疗反应性。
Front Immunol. 2023 Apr 11;14:1105210. doi: 10.3389/fimmu.2023.1105210. eCollection 2023.
4
SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.SYT16 是胶质母细胞瘤的预后生物标志物,并与免疫浸润相关:基于 TCGA 数据的研究。
Int Immunopharmacol. 2020 Jul;84:106490. doi: 10.1016/j.intimp.2020.106490. Epub 2020 Apr 11.
5
Screening TCGA database for prognostic genes in lower grade glioma microenvironment.在TCGA数据库中筛选低级别胶质瘤微环境中的预后基因。
Ann Transl Med. 2020 Mar;8(5):209. doi: 10.21037/atm.2020.01.73.
6
Predictive Panel for Immunotherapy in Low-Grade Glioma.低级别胶质瘤免疫治疗的预测性检测板
World Neurosurg. 2024 Mar;183:e825-e837. doi: 10.1016/j.wneu.2024.01.039. Epub 2024 Jan 11.
7
Immune-Related Gene SERPINE1 Is a Novel Biomarker for Diffuse Lower-Grade Gliomas Large-Scale Analysis.免疫相关基因SERPINE1是弥漫性低级别胶质瘤的新型生物标志物:大规模分析
Front Oncol. 2021 May 20;11:646060. doi: 10.3389/fonc.2021.646060. eCollection 2021.
8
Identification of tumor microenvironment-related genes in lower-grade gliomas by mining TCGA database.通过挖掘TCGA数据库鉴定低级别胶质瘤中肿瘤微环境相关基因
Transl Cancer Res. 2020 Aug;9(8):4583-4595. doi: 10.21037/tcr-20-1079.
9
Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.下一代测序确定 HOXA6 为低级别胶质瘤中的一种新型致癌基因。
Aging (Albany NY). 2022 Mar 29;14(6):2819-2854. doi: 10.18632/aging.203977.
10
CMTM Family Genes Affect Prognosis and Modulate Immunocytes Infiltration in Grade II/III Glioma Patients by Influencing the Tumor Immune Landscape and Activating Associated Immunosuppressing Pathways.CMTM家族基因通过影响肿瘤免疫格局和激活相关免疫抑制途径,影响II/III级胶质瘤患者的预后并调节免疫细胞浸润。
Front Cell Dev Biol. 2022 Feb 17;10:740822. doi: 10.3389/fcell.2022.740822. eCollection 2022.

引用本文的文献

1
Identification of m6A methyltransferase-related WTAP and ZC3H13 predicts immune infiltrates in glioblastoma.m6A甲基转移酶相关的WTAP和ZC3H13的鉴定可预测胶质母细胞瘤中的免疫浸润。
Sci Rep. 2025 Feb 5;15(1):4412. doi: 10.1038/s41598-025-88671-4.
2
IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review.异柠檬酸脱氢酶(IDH)突变、胶质瘤免疫原性以及原发性错配修复缺陷型IDH突变星形细胞瘤(PMMRDIA)的治疗挑战:一项系统综述
Mol Oncol. 2024 Dec;18(12):2822-2841. doi: 10.1002/1878-0261.13598. Epub 2024 Feb 9.
3
Radiomic profiling for insular diffuse glioma stratification with distinct biologic pathway activities.

本文引用的文献

1
Tertiary lymphoid structure stratifies glioma into three distinct tumor subtypes.三级淋巴结构将神经胶质瘤分为三种不同的肿瘤亚型。
Aging (Albany NY). 2021 Dec 26;13(24):26063-26094. doi: 10.18632/aging.203798.
2
Metabolic Signature-Based Subtypes May Pave Novel Ways for Low-Grade Glioma Prognosis and Therapy.基于代谢特征的亚型可能为低级别胶质瘤的预后和治疗开辟新途径。
Front Cell Dev Biol. 2021 Nov 23;9:755776. doi: 10.3389/fcell.2021.755776. eCollection 2021.
3
Co-Encapsulation of Fisetin and Cisplatin into Liposomes for Glioma Therapy: From Formulation to Cell Evaluation.
基于不同生物学通路活性的岛叶弥漫性 glioma 分层的放射组学分析。
Cancer Sci. 2024 Apr;115(4):1261-1272. doi: 10.1111/cas.16089. Epub 2024 Jan 26.
4
Lipid metabolism-related gene expression in the immune microenvironment predicts prognostic outcomes in renal cell carcinoma.免疫微环境中与脂质代谢相关的基因表达可预测肾细胞癌的预后结果。
Front Immunol. 2023 Nov 27;14:1324205. doi: 10.3389/fimmu.2023.1324205. eCollection 2023.
5
The signature of immune-subtype specific driving transcription factors suggest potential drugs for refractory glioblastoma.免疫亚型特异性驱动转录因子的特征表明难治性胶质母细胞瘤的潜在药物。
Am J Cancer Res. 2023 Apr 15;13(4):1278-1294. eCollection 2023.
6
Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.T 细胞功能的正向调节剂可预测低级别神经胶质瘤的预后和微环境特征。
Front Immunol. 2023 Jan 16;13:1089792. doi: 10.3389/fimmu.2022.1089792. eCollection 2022.
7
Identification of Immune-Related lncRNAs for Predicting Prognosis and Immune Landscape Characteristics of Uveal Melanoma.用于预测葡萄膜黑色素瘤预后和免疫景观特征的免疫相关长链非编码RNA的鉴定
J Oncol. 2022 Aug 29;2022:7680657. doi: 10.1155/2022/7680657. eCollection 2022.
8
The role of hypoxia-related genes in TACE-refractory hepatocellular carcinoma: Exploration of prognosis, immunological characteristics and drug resistance based on onco-multi-OMICS approach.缺氧相关基因在经动脉化疗栓塞术难治性肝细胞癌中的作用:基于肿瘤多组学方法对预后、免疫特征和耐药性的探索
Front Pharmacol. 2022 Sep 26;13:1011033. doi: 10.3389/fphar.2022.1011033. eCollection 2022.
9
Exploration of Potential Biomarkers and Immune Landscape for Hepatoblastoma: Evidence from Machine Learning Algorithm.肝母细胞瘤潜在生物标志物与免疫图谱的探索:来自机器学习算法的证据
Evid Based Complement Alternat Med. 2022 Jul 31;2022:2417134. doi: 10.1155/2022/2417134. eCollection 2022.
10
A Nomogram Based on SEER Database for Predicting Prognosis in Patients with Mucinous Ovarian Cancer: A Real-World Study.一项基于监测、流行病学和最终结果(SEER)数据库预测黏液性卵巢癌患者预后的列线图:一项真实世界研究
Int J Womens Health. 2022 Jul 26;14:931-943. doi: 10.2147/IJWH.S372328. eCollection 2022.
将非瑟酮和顺铂共包封于脂质体中用于胶质瘤治疗:从制剂到细胞评估
Pharmaceutics. 2021 Jun 26;13(7):970. doi: 10.3390/pharmaceutics13070970.
4
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类:概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
5
Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy.炎性肿瘤微环境响应性中性粒细胞外泌体为基础的药物传递系统用于靶向脑胶质瘤治疗。
Biomaterials. 2021 Jun;273:120784. doi: 10.1016/j.biomaterials.2021.120784. Epub 2021 Mar 31.
6
Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes.免疫检查点靶向治疗在神经胶质瘤中的应用:现状与展望。
Front Immunol. 2020 Nov 27;11:578877. doi: 10.3389/fimmu.2020.578877. eCollection 2020.
7
Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma.低级别胶质瘤肿瘤突变负荷相关免疫预后模型的建立与验证
Front Oncol. 2020 Aug 20;10:1409. doi: 10.3389/fonc.2020.01409. eCollection 2020.
8
Classification of diffuse lower-grade glioma based on immunological profiling.基于免疫特征分析的弥漫性低级别胶质瘤分类。
Mol Oncol. 2020 Sep;14(9):2081-2095. doi: 10.1002/1878-0261.12707. Epub 2020 Jun 5.
9
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.胶质母细胞瘤中的 IDH 突变:分子机制与潜在治疗靶点。
Br J Cancer. 2020 May;122(11):1580-1589. doi: 10.1038/s41416-020-0814-x. Epub 2020 Apr 15.
10
Correlation between IDH, ATRX, and TERT promoter mutations in glioma.胶质瘤中 IDH、ATRX 和 TERT 启动子突变的相关性。
Brain Tumor Pathol. 2020 Apr;37(2):33-40. doi: 10.1007/s10014-020-00360-4. Epub 2020 Mar 29.